The patenting of human genes has a complex history and significant implications for genetic research and diagnostics. While the U.S. Supreme Court has ruled against the patentability of naturally occurring DNA sequences, other aspects of genetic material and related technologies may still be eligible for patent protection.
Can companies still patent genes?
Following the Supreme Court's decision in Association for Molecular Pathology v. Myriad Genetics, naturally occurring sequences of human DNA are not patentable subject matter [1]. This ruling stems from the principle that laws of nature, natural phenomena, and abstract ideas are not patentable [1][2]. However, complementary DNA (cDNA), which is a synthetic form of DNA created in a laboratory and does not exist in nature, can be patented if it meets other patentability requirements, such as being novel and non-obvious [1][3].
What about genetic diagnostic tests?
Diagnostic methods that involve analyzing gene sequences are also subject to scrutiny. The Myriad case specifically involved patents on methods for diagnosing breast and ovarian cancer risk by analyzing BRCA1 and BRCA2 genes [1]. While the court did not directly rule on the patentability of diagnostic methods themselves, the interpretation of the ruling has led to challenges for patents claiming diagnostic techniques tied to natural gene sequences [4]. However, claims that involve more than just observing a natural phenomenon, such as when a diagnostic method involves significant additional steps or manipulations, may still be patentable [1].
What was the impact of the Myriad Genetics case?
The Myriad Genetics decision significantly impacted the field of genetic diagnostics. Before this ruling, Myriad held patents on the BRCA1 and BRCA2 genes, which allowed them to exclusively offer genetic testing for these mutations. The patents restricted other companies and researchers from performing these tests or developing alternative methods [1][5]. The Supreme Court's decision invalidated these gene patents, opening the door for broader access to genetic testing and fostering competition in the diagnostic market [1][4].
What are the arguments for and against gene patenting?
Arguments in favor of gene patenting often center on incentivizing innovation. Proponents suggest that patents encourage companies to invest heavily in research and development of new genetic tests and therapies by providing a period of exclusivity and the potential for recouping development costs [6]. Conversely, opponents argue that patenting human genes hinders scientific progress, limits patient access to essential diagnostic tests due to high costs, and raises ethical concerns about the ownership of human genetic material [2][7]. The debate highlights a tension between intellectual property rights and the public's interest in advancing medical knowledge and ensuring equitable healthcare access.